NOTE 21 - SUBSEQUENT EVENTS

As of March 31, 2025 the Company issued an aggregate of 191,522 shares of its common stock for consulting services, the Company’s Board of Directors’ stock compensation, the Company’s President stock compensation, one amended promissory note valued at $68,723.

As of March 31, 2025 the Company entered into two exchange agreements whereby the parties agreed to exchange the total of $765,885 owed by the Company for 1,874,079 shares of restricted Common Stock.

As of March 31, 2025 the Company issued an aggregate of 234,482 shares of its common stock in connection with cashless exercise of warrants.

On March 4, 2025, the Company, the Company’s subsidiary BioCorRx Pharmaceuticals, Inc., a majority owned subsidiary of the Company, and USWM, LLC (the “Seller”) entered into an Asset Purchase Agreement (the “APA”)..

Pursuant to the APA, BioCorRx Pharmaceuticals, Inc. purchased certain assets and assumed certain liabilities related to Lucemyra, an FDA approved prescription medication for opioid withdrawal. The upfront purchase price was $400,000 to be paid via Seller’s retention, until such amounts equal $400,000 of fifty percent (50%) of the Net Sales (as defined in the APA) of Lucemyra and fifty percent (50%) of the Net Distributable Profits of the generic version of Lucemyra. 

As a condition to the closing of the APA, the Company and the Seller entered into a Securities Purchase Agreement (the “SPA”) whereby the Company, as part of the consideration paid to the Seller for the purchase of the assets, agreed to issue five hundred thousand (500,000) shares of the Company’s Common Stock and to issue a warrant to the Seller for the purchase of five hundred thousand (500,000) shares of Common Stock, which is exercisable for two years and has an exercise price of $1.00 per share.